Similar Search Results

Group living for elderly patients with dementia -- A cost analysis

Svensson, Marianne; Edebalk, Per Gunnar; Persson, Ulf - In: Health Policy 38 (1996) 2, pp. 83-100

Persistent link: https://www.econbiz.de/10005516183

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

Willis, Michael; Svensson, Marianne; Löthgren, Mickael; … - In: The European Journal of Health Economics 11 (2010) 6, pp. 585-594

Persistent link: https://www.econbiz.de/10008775862

Measuring the end-of-life premium in cancer using individual ex ante willingness to pay

Olofsson, Sara; Gerdtham, Ulf-G.; Hultkrantz, Lars; … - In: The European journal of health economics : HEPAC ; … 19 (2018) 6, pp. 807-820

Persistent link: https://www.econbiz.de/10011947254

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board — LFN (now called the Dental and Pharmaceutical Benefits agency — TLV) since 2002. VBP has the character of a monopoly system, leading to...

Persistent link: https://www.econbiz.de/10011000768

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 11 (2013) 1, pp. 83-84

Persistent link: https://www.econbiz.de/10011000861

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

Persson, Ulf; Willis, Michael; Ödegaard, Knut - In: The European Journal of Health Economics 11 (2010) 2, pp. 195-203

Persistent link: https://www.econbiz.de/10009404141

Reimbursement and clinical guidance for pharmaceuticals in Sweden

Anell, Anders; Persson, Ulf - In: The European Journal of Health Economics 6 (2005) 3, pp. 274-279

Persistent link: https://www.econbiz.de/10009404270

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board - LFN (now called the Dental and Pharmaceutical Benefits agency - TLV) since 2002. VBP has the character of a monopoly system, leading to reimbursement...

Persistent link: https://www.econbiz.de/10010552620

Value of a QALY and VSI estimated with the chained approach

Olofsson, Sara; Gerdtham, Ulf-G.; Hultkrantz, Lars; … - In: The European journal of health economics : HEPAC ; … 20 (2019) 7, pp. 1063-1077

Persistent link: https://www.econbiz.de/10012220983

The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria : a time trade-off and discrete choice experiment study

Olofsson, Sara; Gralén, Katarina; Hoxer, Christina; … - In: The European journal of health economics 23 (2022) 6, pp. 993-1005

Persistent link: https://www.econbiz.de/10013406961